GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » EPS without NRI

Laurus Labs (BOM:540222) EPS without NRI : ₹2.97 (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs EPS without NRI?

Laurus Labs's earnings per share without non-recurring items for the three months ended in Mar. 2024 was ₹1.40. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2.97.

During the past 12 months, Laurus Labs's average earnings per share (NRI) Growth Rate was -79.70% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was -45.40% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 18.40% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 18.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Laurus Labs's EPS without NRI or its related term are showing as below:

BOM:540222' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -45.4   Med: 22.85   Max: 107.6
Current: -45.4

During the past 11 years, Laurus Labs's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 107.60% per year. The lowest was -45.40% per year. And the median was 22.85% per year.

BOM:540222's 3-Year EPS without NRI Growth Rate is ranked worse than
91.84% of 846 companies
in the Drug Manufacturers industry
Industry Median: 9.2 vs BOM:540222: -45.40

Laurus Labs's EPS (Diluted) for the three months ended in Mar. 2024 was ₹1.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2.97.

Laurus Labs's EPS (Basic) for the three months ended in Mar. 2024 was ₹1.40. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2.98.


Laurus Labs EPS without NRI Historical Data

The historical data trend for Laurus Labs's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs EPS without NRI Chart

Laurus Labs Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.80 18.29 15.34 14.64 2.97

Laurus Labs Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 0.46 0.68 0.43 1.40

Competitive Comparison of Laurus Labs's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Laurus Labs's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Laurus Labs's PE Ratio without NRI falls into.



Laurus Labs EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Laurus Labs  (BOM:540222) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Laurus Labs EPS without NRI Related Terms

Thank you for viewing the detailed overview of Laurus Labs's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Laurus Labs (BOM:540222) Business Description

Traded in Other Exchanges
Address
Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs (BOM:540222) Headlines

No Headlines